Mitochondrial Dysfunction in Ulcerative Colitis: Pathogenic Mechanisms and Novel Therapeutics.

Area of Science:

• Gastroenterology
• Immunology
• Mitochondrial Biology

Background:

• Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by mitochondrial dysfunction.
• Mitochondrial defects in UC impair energy production, increase oxidative stress, and disrupt immune balance.
• This dysfunction creates a self-perpetuating inflammatory cycle via metabolic-immune crosstalk and mitochondrial damage.

Purpose of the Study:

• To review therapeutic strategies targeting mitochondrial pathways in ulcerative colitis.
• To synthesize current evidence on mitochondrial dysfunction in UC, linking molecular mechanisms to immune-metabolic interactions.
• To propose a novel treatment paradigm focused on mitochondrial restoration for UC.

Main Methods:

• Review of scientific literature on mitochondrial dysfunction in ulcerative colitis.
• Analysis of therapeutic classes including antioxidants, metabolic modulators, and microbiota-directed strategies.
• Examination of preclinical and early clinical data for emerging mitochondrial-targeting agents.

Main Results:

• Mitochondrial dysfunction exacerbates UC through metabolic-immune crosstalk, mtDNA leakage, and cardiolipin redistribution.
• Bidirectional crosstalk between gut microbiota and mitochondria amplifies intestinal inflammation in UC.
• Agents like MitoQ, ClpP activators, and engineered probiotics demonstrate therapeutic potential by restoring mitochondrial function.

Conclusions:

• Mitochondrial dysfunction is a central driver of ulcerative colitis pathogenesis.
• Targeting mitochondrial pathways offers a promising therapeutic avenue for UC treatment.
• Restoring mitochondrial function represents a potential new paradigm for managing ulcerative colitis.